Major depressive episodes and diet pills

REFERENCES

• American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, 4th edn. American Psychiatric Association, Washington, USA (1994).
   Google Scholar
• FOGEL BS: Major depression versus organic mood disorder: a questionable distinction.' Clin. Psychiatry (1990) 51:53–56.
   PubMedGoogle Scholar
• •This paper, and the one below it, describe some of the difficulties encountered when attempting to relate depression to an organic cause such as a drug.
   Google Scholar
• LAVORATO DH, PATTEN SB: Antihypertensive medications and depression, an historical perspective. Pharmacoepidemiol. Drug Sal (2000) 8:355–359.
   Google Scholar
• CARPENTER KM, HASIN DS, ALLISON DB, FAITH MS: Relationships between obesity and DSM-IV major depressive disorder, suicide ideation, and suicide attempts: results from a general population study. Am. I Public Health (2000) 90:251–257.
   PubMed Web of Science ®Google Scholar
• PATTEN SB: 'Diet pills' and major depression in the Canadian population. Can. J. Psychiatry (2001) 46:438–440.
   PubMedGoogle Scholar
• ••This was an epidemiological studyconfirming the association between self-reported consumption of 'diet pills' and depression in a large, randomly sample from the general population.
   Google Scholar
• CARGILL BR, CLARK MM, PERA V, NIAURA RS, ABRAMS DB: Binge eating, body image, depression, and self-efficacy in an obese clinical population. Obesity Res. (1999) 7:379–386.
   PubMedGoogle Scholar
• GLUCK ME, GELIEBTER A, SATOV T: Night eating syndrome is associated with depression, low self-esteem, reduced daytime hunger, and less weight loss in obese outpatients. Obesity Res. (2001) 9:264–267.
   PubMedGoogle Scholar
• POLIVY J: Psychological consequences offood restriction. J Am. Diet Assoc. (1996) 96:589–592.
   PubMed Web of Science ®Google Scholar
• CARNEY RM, FREEDLAND KE, EISENSA, RICH MW, JAFFE AS: Major depression and medication adherence in elderly patients with coronary artery disease. Health Psycho]. (1995) 14:88–90.
   PubMed Web of Science ®Google Scholar
• GLAZER G: Long-term pharmacotherapy of obesity 2000. A review of efficacy and safety. Arch. Intern. Med. (2001) 161:1824.
   Google Scholar
• TWERSKI B: Sympathomimetic-induced
   Google Scholar
• •• depression. Arn .1 Psychiatry (1987) 144:252.
   Google Scholar
• ROSENFELD AA: Depression and psychotic regression following prolonged methylphenidate use and withdrawal: case report. Am. 1. Psychiatry(1979) 136:226–228.
   PubMed Web of Science ®Google Scholar
• GRIGG JR, GOYER PF: Phenylpropanolamine anorexiants and affective disorders. Mil Med. (1986) 151:387–388.
   PubMedGoogle Scholar
• BROWN RT, BORDEN KA, SPUNT AL, MEDENIS R: Depression following pemoline withdrawal in a hyperactive child. Clin. Pediam (1985) 24:174.
   PubMedGoogle Scholar
• SCHILDKRAUT JJ, WATSON R, DRASKOCZY PR: Amphetamine withdrawal: depression and M.H.PG. excretion. Lancet (1971) 2:485–486.
   PubMed Web of Science ®Google Scholar
• TUMA TA. Depressive stupor following amphetamine withdrawal. Br. j. Hosp. Pract. (1993) 49:361–363.
   Google Scholar
• STEEL JM, BRIGGS M: Withdrawal depression in obese patients after fenfluramine treatment. Br. Med. J. (1972) 3:26–27.
   PubMedGoogle Scholar
• GREDEN JF, FONTAINE P, LUBETSKY M, CHAMBERLIN K: Anxiety and depression associated with caffeinism among psychiatric inpatients. Am. 1. Psychiatry (1978) 135:963–966.
   PubMed Web of Science ®Google Scholar
• MINO Y, YASUDA N, FUJIMURA T, OHARA H: Caffeine consumption and anxiety and depressive symptomatology among medical students. Arukom Kenkyuto Yakubutsu Bon. (1990) 25:486–496.
   PubMedGoogle Scholar
• JACOBSEN BK, HANSEN V: Caffeine and health. Br. Med. J. (1988) 296:291.
   PubMedGoogle Scholar
• ••Many over the counter weight loss pillscontain appreciable quantities of caffeine. Here, the potential for emotional changes during caffeine withdrawal is documented.
   Google Scholar
• SILVERMAN K, EVANS SM, STRAIN EC, GRIFFITHS RR: Withdrawal syndrome after the double-blind cessation of caffeine consumption. N Engl. I Med. (1992) 327:1109–1114.
   PubMed Web of Science ®Google Scholar
• WENOKUR B, LESSEM P: Caffeine withdrawal, metoclopramide, and depression. Am. 1. Castroenterol (1993) 88:1464.
   Google Scholar
• RIHMER Z, REVAI K, ARATO M, PERENYI A: Two case reports of mazindol-induced depression. Am. I Psychiatry (1984) 141:1497–1498.
   PubMedGoogle Scholar
• CAPLAN J: Habituation to diethypropion(Tenuate). Can. Med. Assoc. 1 (1963) 88:943–944.
   PubMedGoogle Scholar
• HALLE MT, DILSAVER SC: Tranylcypromine withdrawal phenomena. I Psychiatr. Neurosci. (1993) 18:49–50.
   PubMedGoogle Scholar
• TOORNVLIET AC, PIJL H, MEINDERS AE: Major depression during dexfenfluramine treatment. Int. Obes. Relat. Metab. Disord. (1994) 18:650.
   PubMedGoogle Scholar
• HARDING T: Fenfluramine dependence. Br. Med. J. (1971) 3:305.
   PubMedGoogle Scholar
• HARDING T: Depression following fenfluramine withdrawal. Br. I Psychiatry (1972) 121:338–339.
   PubMedGoogle Scholar
• OSWALD I, LEWIS SA, DUNLEAVY DLF, BREZINOVA V, BRIGGS M: Drugs of dependence though not of abuse: fenfluramine and imipramine. Br. Med. I (1971) 3:70–73.
   PubMed Web of Science ®Google Scholar
• ••These authors demonstrated, in a studywith volunteer subjects, that depressive symptoms peaked about 4 days after withdrawal of fenfluramine
   Google Scholar
• GOLDING D: Unusual effect of fenfluramine. Br. Med. I (1970) 1:238.
   PubMedGoogle Scholar
• MCCANN UD, ELIGULASHVILI V, RICAURTE GA: Adverse neuropsychiatric events associated with dexfenfluramine and fenfluramine. Frog. Neuropsychopharmacol Biol. Psychiatry(1998) 22:1087–1102.
   PubMedGoogle Scholar
• ZIMMER JE, GREGORY RJ: Bipolar depression associated with fenfluramine and phentermine. Am. J. Psychiatry (1998) 59:383–384.
   Google Scholar
• WIRTH A, KRAUSE J: Long-term weight loss with sibutramine. JAMA (2001) 286:1331–1339.
   PubMed Web of Science ®Google Scholar
• DUJOVNE CA, ZAVORALJH, ROWE E, MENDEL CM: Effects of sibutramine on body weight and serum lipids: a double-blind, randomized, placebo-controlled study in 322 overweight and obese patients with dyslipidemia. Am. Heart.! (2001) 142:489–497.
   PubMed Web of Science ®Google Scholar
• JAMES WPT, ASTRUP A, FINER N, et al.: Effect of sibutramine on weight maintenance after weight loss: a randomised trial. Lancet (2000) 356:2119–2125.
   Google Scholar
• TRAKAS K, SHEAR NH: Serotonin syndrome risk with antiobesity drug. Can. I Chia. Pharm. (2000) 7:216.
   Google Scholar
• •This letter draws attention to possible neurotoxicity arising from combined use of antidepressants and sibutramine
   Google Scholar
• SHORVON SD, CARNEY MWP, CHANARIN I, REYNOLDS EH: The neuropsychiatry of megaloblastic anaemia. Br. Med. J. (1980) 281:1036–1038.
   PubMedGoogle Scholar
• NAGELE H, PETERSEN B, BONACKER U, RODIGER W: Effect of orlistat on blood cyclosporin concentration in an obese heart transplant patient. Eur. I Chia. Pharmacol (1999) 55:667–669.
   PubMed Web of Science ®Google Scholar
• BENAZZI F: Depression induced by orlistat. Can. I Psychiatry (2000) 45:87.
   PubMed Web of Science ®Google Scholar
• KESSLER RC, ANDREWS G, MROCZEK D, USTUN B, WITTCHEN HU: The World Health Organization composite international diagnostic interview short-form (CIDI-SF). Internat. I Methods Psychiatr. Res. (1998) 7:171–185.
   Google Scholar
• US PREVENTIVE SERVICES TASK FORCE: Screening for depression: recommendations and rational. Ann. Int. Med. (2002) 136:760–764.
   PubMed Web of Science ®Google Scholar